Mediathek

Bioprinting is an emerging technology with the potential to fabricate functional in vitro 3D models of different tissues, enabling more predictive and physiological relevant drug development. However, suitable bioinks that fulfil good printability and biofunctionality, e.g., allowing cell adhesion and self-organization, are still limited.

Despite recent advances in neuropsychiatry, translational development for many targets remains challenging, particularly when receptors exist as families with complex subunit-dependent pharmacology and safety concerns. This is the case for NMDA receptor (NMDAR) antagonists. R,S-ketamine illustrates this issue.

This study demonstrates the implementation of a structured developability assessment strategy for sdAb conjugates. The approach integrates physicochemical and functional stability evaluations, supporting robust candidate selection, formulation development, and method optimization for this class of molecules.

Emerging immune-evasive viral variants threaten the efficacy of current vaccines, underscoring the need for strategies that elicit broad and durable protection. Heterologous prime-boost regimens combining distinct vaccine platforms can enhance humoral and cellular immunity through complementary mechanisms.

NfL and GFAP in blood are emerging as important biomarkers in MS. A urine-based assay could provide a simpler, non-invasive alternative; however, limited biomarker transfer into urine may pose a major challenge. This study aimed to evaluate the detectability and diagnostic potential of urinary and serum NfL and GFAP for distinguishing MS patients from healthy controls.

The durability of vaccine-induced immunity is often limited by waning responses, antigenic drift, and anti-vector immunity, highlighting the need for innovative vaccination strategies. Heterologous prime–boost approaches can help overcome these barriers by exploiting the complementary strengths of distinct platforms.